Published on January 21, 2020
Background
In this trial, 137 cancer patients with NO AVAILABLE STANDARD THERAPEUTIC OPTIONS were treated with the combination of Lenvima plus Keytruda.
Eligible patients had metastatic Renal Cell Carcinoma (RCC), Endometrial Cancer, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Melanoma, Non-Small-Cell Lung Cancer (NSCLC) and Urothelial Cancer.
Results
At 24 weeks, this is the percentage of patients that were still responding to the combination and their cancer has stopped from continuous growing and/or has shrunk:
- 63% of Renal Cell Cancer patients
- 52% of Endometrial Cancer patients
- 48% of Melanoma patients
- 36% SCCHN
- 33% NSCLC
- 25%Urothelial Cancer
Adverse Events
The most common treatment-related adverse events were fatigue (58%), diarrhea (52%), hypertension (47%), and hypothyroidism (42%).
Conclusion
The combination of Lenvima plus Keytruda had promising efficacy among patients with selected solid tumors, with a manageable safety profile.
The best treatment for a cancer patient is to get the most advanced cancer drugs in advanced stages of development. There, the hope and the chance to extend life go far beyond the standard protocols.
Contact us to find out what is the best treatment for YOU
TRIAL•IN Pharma
Do not give up on life!
Contact us 24/7 for free service matching:
Call center +44.2082.426.039
